JP Morgan Cazenove recorded BTG PLC (LON:BTG), retaining its price target at 790.00GBX earlier today
- Updated: September 18, 2016
Yesterday BTG PLC (LON:BTG) traded 4.79% higher at 591.50GBX. The company’s 50-day average is 627.72GBX and its two hundred day average is 638.45GBX. With the last stock close down 1.03% from the two hundred day average, compared to the S&P 500 Index which has decreased -0.01% over the same time period. 1,142,541 shares of the stock exchanged hands, up from ann avg. trading volume of 671,071.
JP Morgan Cazenove held the target stock price of BTG PLC (LON:BTG) at 790GBX, reporting a possible upside of 0.34%,
On 7/15/2016, Jefferies released a statement on BTG PLC(LON:BTG) upped the target price from 0.00GBX to 860.00GBX. At the time, this suggested an upside of 0.27%.
BTG PLC has a one-year low of 504.00GBX and a 52 week high of 739.50GBX with a PE ratio of 41. BTG’s total market value is presently 0.0 GBX.
Brief Synopsis On BTG PLC (LON:BTG)
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment’s products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, and hip replacement and multiple sclerosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.